{"id":"low-dose-cannabidiol","safety":{"commonSideEffects":[{"rate":null,"effect":"Fatigue"},{"rate":null,"effect":"Diarrhea"},{"rate":null,"effect":"Changes in appetite"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Drug-drug interactions via CYP3A4 inhibition"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Cannabidiol (CBD) is a non-intoxicating cannabinoid that interacts with cannabinoid receptors and multiple other molecular targets including serotonin receptors, TRPV1 channels, and adenosine receptors. At low doses, it exerts anti-inflammatory, anxiolytic, and neuroprotective effects by modulating endocannabinoid tone and reducing neuroinflammatory cascades. The low-dose formulation is designed to optimize therapeutic benefit while minimizing potential adverse effects associated with higher CBD exposures.","oneSentence":"Low-dose cannabidiol modulates endocannabinoid signaling and reduces neuroinflammation through CB1/CB2 receptor interactions and non-receptor pathways.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:19:33.158Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Anxiety disorders"},{"name":"Epilepsy"},{"name":"Neuroinflammatory conditions"}]},"trialDetails":[{"nctId":"NCT07123467","phase":"PHASE3","title":"Cannabidiol-Assisted Learning for Managing Generalized Anxiety Disorder","status":"RECRUITING","sponsor":"Wayne State University","startDate":"2025-11-03","conditions":"Generalized Anxiety Disorder (GAD), Anxiety Disorders","enrollment":90},{"nctId":"NCT06854783","phase":"PHASE1","title":"Safety and Pharmacokinetics of Cannabidiol in Healthy Volunteers","status":"COMPLETED","sponsor":"Tiamat Australia Pty Ltd","startDate":"2025-07-14","conditions":"Pharmacokinetics","enrollment":20},{"nctId":"NCT07148843","phase":"PHASE2, PHASE3","title":"Cannabidiol as an Adjunct Treatment for Alcohol Withdrawal and Craving","status":"NOT_YET_RECRUITING","sponsor":"Johns Hopkins University","startDate":"2026-04-01","conditions":"Alcohol Use Disorder (AUD), Withdrawal From Addictive Substance; Detoxification, Craving","enrollment":105},{"nctId":"NCT06615284","phase":"PHASE1","title":"A Study of Atorvo+™ in Healthy Adult Participants","status":"COMPLETED","sponsor":"Indication Bioscience LLC","startDate":"2025-01-28","conditions":"Coronary Heart Disease, Dyslipidemias","enrollment":24},{"nctId":"NCT04816994","phase":"PHASE3","title":"Effect of Cannabis Extract on Acute Radicular Pain and on Analgesic Requirement","status":"RECRUITING","sponsor":"Hadassah Medical Organization","startDate":"2018-01-07","conditions":"Acute Radicular Back Pain, Cannabis","enrollment":200},{"nctId":"NCT06448923","phase":"PHASE2","title":"Cannabidiol After Multi-Trauma for Pain and Opioid Therapy","status":"RECRUITING","sponsor":"Centre Integre Universitaire de Sante et Services Sociaux du Nord de l'ile de Montreal","startDate":"2025-06-01","conditions":"Fracture","enrollment":225},{"nctId":"NCT04398719","phase":"EARLY_PHASE1","title":"CBD-Microglia PET Study","status":"RECRUITING","sponsor":"Yale University","startDate":"2021-05-07","conditions":"CBD, Healthy","enrollment":15},{"nctId":"NCT04527003","phase":"PHASE3","title":"Cannabidiol and Management of Endometriosis Pain","status":"TERMINATED","sponsor":"Milton S. Hershey Medical Center","startDate":"2020-12-04","conditions":"Endometriosis, CBD, Pelvic Pain","enrollment":12},{"nctId":"NCT06692933","phase":"EARLY_PHASE1","title":"Effects of a Hemp Product on the Pharmacokinetics and Pharmacodynamics of Clopidogrel","status":"RECRUITING","sponsor":"Washington State University","startDate":"2024-06-20","conditions":"Interaction","enrollment":24},{"nctId":"NCT05678881","phase":"PHASE1","title":"Safety, Tolerability, and Efficacy of RLS103 in a Clinical Model of Photosensitive Epilepsy","status":"TERMINATED","sponsor":"Receptor Life Sciences","startDate":"2022-04-25","conditions":"Epilepsy","enrollment":2},{"nctId":"NCT05407285","phase":"PHASE1, PHASE2","title":"A Study of Ingested Cannabidiol in Healthy Occasional Cannabis Users","status":"COMPLETED","sponsor":"Centre hospitalier de l'Université de Montréal (CHUM)","startDate":"2022-07-22","conditions":"Cannabis","enrollment":70},{"nctId":"NCT02283281","phase":"PHASE2, PHASE3","title":"Anesthetic Premedication With a Cannabis Extract (Cannapremed)","status":"UNKNOWN","sponsor":"Hadassah Medical Organization","startDate":"2015-05","conditions":"Pain, Postoperative, Postoperative Nausea and Vomiting, Anxiety","enrollment":200},{"nctId":"NCT05044936","phase":"EARLY_PHASE1","title":"Topical Cannabidiol Cream and Post-exercise Recovery","status":"WITHDRAWN","sponsor":"University of New Mexico","startDate":"2023-05-15","conditions":"Muscle Damage","enrollment":""},{"nctId":"NCT04193631","phase":"PHASE1","title":"Low Dose of Cannabidiol (CBD) to Treat Mild to Moderate Musculoskeletal Pain","status":"COMPLETED","sponsor":"Pure Green","startDate":"2019-12-07","conditions":"Musculoskeletal Pain","enrollment":16},{"nctId":"NCT03763851","phase":"PHASE2","title":"Cannabis Oil and Radiation Therapy for the Management of Pain","status":"TERMINATED","sponsor":"Tetra Bio-Pharma","startDate":"2018-03-14","conditions":"Metastatic Prostate Cancer, Lung Cancer, Breast Cancer","enrollment":100},{"nctId":"NCT02324673","phase":"PHASE1, PHASE2","title":"Cannabidiol Oral Solution in Pediatric Participants With Treatment-resistant Seizure Disorders","status":"COMPLETED","sponsor":"INSYS Therapeutics Inc","startDate":"2015-04-13","conditions":"Seizures","enrollment":61},{"nctId":"NCT02478424","phase":"PHASE2","title":"Extended Use of Cannabidiol for the Prevention of Graft-versus-host-disease","status":"UNKNOWN","sponsor":"Rabin Medical Center","startDate":"2015-07","conditions":"Graft vs Host Disease","enrollment":10},{"nctId":"NCT00530764","phase":"PHASE2","title":"A Study of Sativex® for Pain Relief in Patients With Advanced Malignancy.","status":"COMPLETED","sponsor":"GW Pharmaceuticals Ltd","startDate":"2007-11","conditions":"Palliative Care, Pain, Cancer","enrollment":360}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":13,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["EPIDIOLEX®"],"phase":"phase_3","status":"active","brandName":"Low-Dose Cannabidiol","genericName":"Low-Dose Cannabidiol","companyName":"Wayne State University","companyId":"wayne-state-university","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Low-Dose Cannabidiol has been studied for various conditions, including fractures, seizures, acute radicular back pain, and musculoskeletal pain, in clinical trials. It is a small molecule that functions as a cannabinoid CB1 receptor negative allosteric modulator, which is a specific mechanism of action.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}